Why is Balaxi Pharma falling/rising?

As of 11-Aug, Balaxi Pharmaceuticals Ltd is experiencing a price increase, currently trading at 49.10, which reflects a rise of 5.43 or 12.43%. The stock has outperformed its sector today by 11.74%, and its delivery volume has significantly increased by 456.34% compared to the 5-day average, indicating rising investor participation. However, despite this positive movement, the stock has a troubling history, with a year-to-date return of -32.10% and a one-year return of -55.14%. The company's fundamentals show strong long-term potential with an average Return on Equity (ROE) of 30.97%, but recent negative financial results, including a -70.93% drop in profit before tax and a -95.5% decline in profit after tax, raise concerns about its immediate performance. Additionally, institutional investors have reduced their stake by 7.16%, which may reflect a lack of confidence in the company's future.
In the broader market context, Balaxi Pharmaceuticals has outperformed the Sensex in the short term, with a weekly return of +5.09% compared to the benchmark's -0.56%. However, the stock's long-term performance remains below par, as it has underperformed the BSE500 over the past three years, one year, and three months. While the recent price increase may attract some attention, the overall negative trends in profitability and institutional participation suggest that caution is warranted for potential investors.